Search Prime Grants

2222933

Cooperative Agreement

Overview

Grant Description
SBIR Phase II: Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a label-free, biological sample preparation and cell isolation platform for recovery of rare cells from a variety of sample inputs. Specifically, by carrying out sample preparation, manipulation, and monitoring on a single chip platform for selective cell recovery, the sample handling steps will be greatly reduced, thereby ensuring the maintenance of cell viability, improving sample consistency, and sustaining native cell behaviors.

This recovered sample is essential for the development of cell-based therapies in regenerative medicine and cancer management. Personalized medicine also requires precision cell recoveries. This Small Business Technology Transfer (STTR) Phase I project will develop an electrically functional microfluidic sample manipulation platform for phenotype-selective recovery of cells, based on their biophysical attributes. Specifically, microfluidic designs will be integrated to swap cells from complex biological inputs into an optimized buffer to enable cell manipulation. Also, instrumentation will be developed for on-chip monitoring of the sample during various stages of the phenotype-selective cell recovery process.

Further, a variety of sample inputs will be validated on the designed devices to ensure performance, consistency, and reliability for translation into commercial product lines. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22552
Place of Performance
Blacksburg, Virginia 24060-0005 United States
Geographic Scope
Single Zip Code
Related Opportunity
22-552
Analysis Notes
Amendment Since initial award the End Date has been extended from 01/31/25 to 01/31/26 and the total obligations have increased 36% from $952,558 to $1,294,758.
Cytorecovery was awarded Cooperative Agreement 2222933 worth $1,294,758 from in February 2023 with work to be completed primarily in Blacksburg Virginia United States. The grant has a duration of 3 years and was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.

SBIR Details

Research Type
SBIR Phase II
Title
SBIR Phase II:Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a label-free, biological sample preparation and cell isolation platform for recovery of rare cells from a variety of sample inputs. Specifically, by carrying out sample preparation, manipulation, and monitoring on a single chip platform for selective cell recovery, the sample handling steps will be greatly reduced, thereby ensuring the maintenance of cell viability, improving sample consistency, and sustaining native cell behaviors. This recovered sample is essential for the development of cell-based therapies in regenerative medicine and cancer management. Personalized medicine also requires precision cell recoveries._x000D_ _x000D_ This Small Business Technology Transfer (STTR) Phase I project will develop an electrically functional microfluidic sample manipulation platform for phenotype-selective recovery of cells, based on their biophysical attributes. Specifically, microfluidic designs will be integrated to swap cells from complex biological inputs into an optimized buffer to enable cell manipulation. Also, instrumentation will be developed for on-chip monitoring of the sample during various stages of the phenotype-selective cell recovery process. Further, a variety of sample inputs will be validated on the designed devices to ensure performance, consistency, and reliability for translation into commercial product lines._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 22-552

Status
(Ongoing)

Last Modified 5/5/25

Period of Performance
2/15/23
Start Date
1/31/26
End Date
85.0% Complete

Funding Split
$1.3M
Federal Obligation
$0.0
Non-Federal Obligation
$1.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to 2222933

Transaction History

Modifications to 2222933

Additional Detail

Award ID FAIN
2222933
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
YE7LS83NPML7
Awardee CAGE
87PN6
Performance District
VA-09
Senators
Mark Warner
Timothy Kaine

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Research and Related Activities, National Science Foundation (049-0100) General science and basic research Grants, subsidies, and contributions (41.0) $952,558 100%
Modified: 5/5/25